Provided by Tiger Trade Technology Pte. Ltd.

Weight Loss Drugs

1,569.77
-2.7697-0.18%
Number of Gainers:2
Number of Losers:5
Number of Flat:- -
PE:- -
High:1,588.44
Open:1,572.59
Low:1,566.72
Close:1,572.54
Volume:49.63M
Turnover:4.82B
Market Cap:1.64T
Float Cap:1.57T

Loading ...

Amgen - Study Meets Secondary Endpoints for Progression-Free Survival and Objective Response Rate

THOMSON REUTERS
·
Sep 08

Amgen - no New or Unexpected Safety Signals Identified in Dellphi-305 Study

THOMSON REUTERS
·
Sep 08

Update: US Equity Futures Mostly Lower as Traders Assess Rising Oil, Canadian Retaliatory Tariffs

MT Newswires Live
·
Sep 08

Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Guardant Health (GH) and Neurocrine (NBIX)

TIPRANKS
·
Sep 08

Political and General News Events from September 8

Reuters
·
Sep 08

Structure Therapeutics Releases Amylin and GLP-1 Program Presentation

Reuters
·
Sep 08

Structure Therapeutics Reports Phase 1/2a Data Showing 3.3% Weight Loss for Oral Amylin Agonist ACCG-2671

Reuters
·
Sep 08

Structure Therapeutics - Aleniglipron Demonstrates up to 16.2% Body Weight Reduction at 72 Weeks in Access Ole Trial

THOMSON REUTERS
·
Sep 08

Structure Therapeutics - Accg-2671 Demonstrates About 6-Day Half-Life, no Serious Adverse Events, 3.3% Body Weight Loss in Phase 1/2a Sad Trial

THOMSON REUTERS
·
Sep 08

Structure Therapeutics - Additional Clinical Data for Aleniglipron Expected in Q4 2026

THOMSON REUTERS
·
Sep 08

Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and Glp-1 Programs for Chronic Weight Management

THOMSON REUTERS
·
Sep 08

Structure Therapeutics - First Participants Dosed with Accg-2671 in 12-Week Mad Phase 1/2a Trial; Topline Data Expected 1H 2027

THOMSON REUTERS
·
Sep 08

【US Pre-Market】Middle East Energy Risks Escalate, Brent Crude Nears $100, Oil and Gas Stocks Rise; Novartis Plunges 13%

TradingKey
·
Sep 08

Intel, Amgen, Novartis, Bloom Energy, and More Stocks That Explain Today's Market

Dow Jones
·
Sep 08

Plastic Surgery is Booming with Boomers. Here's How to Cash in on the Antiaging Craze.

Dow Jones
·
Sep 08

Beneath the Surface, the Next Market Leaders are Getting Ready to Break Out, Says Morgan Stanley

Dow Jones
·
Sep 08

Ionis Pharma Tumbles After Heart Drug Fails Late-Stage Trial

Reuters
·
Sep 08

Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026

GlobeNewswire
·
Sep 08

Why Amgen Stock is Dropping After Swiss Rival's Trial Setback

Dow Jones
·
Sep 08

Amgen Falls After Novartis Trial Setback, BMO Downgrade

Reuters
·
Sep 08